Please use this identifier to cite or link to this item:
Title: Primary Intravitreal Bevacizumab for Diffuse Diabetic Macular Edema the Pan-American Collaborative Retina Study Group at 24 Months
Authors: Fernando Arevalo, J.
Sanchez, Juan G.
Wu, Lihteh
Maia, Mauricio [UNIFESP]
Alezzandrini, Arturo A.
Brito, Miguel
Bonafonte, Sergio
Lujan, Silvio
Diaz-Llopis, Manuel
Restrepo, Natalia
Rodriguez, Francisco J.
Udaondo-Mirete, Patricia
Clin Oftalmol Ctr Caracas
Inst Cirugia Ocular
Universidade Federal de São Paulo (UNIFESP)
Univ Buenos Aires
Ctr Oftalmol Bonafonte Barcelona
MACULA D&T Diagnost Tratamiento & Rehabil Visual
Gen Univ Valencia
Univ Nacl Rosario
Issue Date: 1-Aug-2009
Publisher: Elsevier B.V.
Citation: Ophthalmology. New York: Elsevier B.V., v. 116, n. 8, p. 1488-1497, 2009.
Abstract: Purpose: To report the 24-month anatomic and Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) response after primary intravitreal bevacizumab (Avastin; Genentech, Inc., San Francisco, CA; 1.25 or 2.5 mg) in patients with diffuse diabetic macular edema (DDME). in addition, a comparison of the 2 different doses of intravitreal bevacizumab (IVB) used is presented.Design: Retrospective, multicenter, interventional, comparative case series.Participants: the clinical records of 115 consecutive patients (139 eyes) with DDME at 11 centers from 8 countries were reviewed.Methods: Patients were treated with at least 1 intravitreal injection of 1.25 or 2.5 mg of bevacizumab. All patients were followed up for 24 months. Patients underwent ETDRS BCVA testing, ophthalmoscopic examination, optical coherence tomography (OCT), and fluorescein angiography (FA) at the baseline, 1-, 3-, 6-, 12-, and 24-month visits.Main Outcome Measures: Changes in BCVA and OCT results.Results: the mean age of the patients was 59.4 +/- 11.1 years. the mean number of IVB injections per eye was 5.8 (range, 1-15 injections). in the 1.25-mg group at 1 month, BCVA improved from 20/150 (0.88 logarithm of the minimum angle of resolution [logMAR] units) to 20/107, 0.76 logMAR units (P<0.0001). the mean IBCVA at 24 months was 20/75 (0.57 logMAR units; P<0.0001). Similar BCVA changes were observed in the 2.5-mg group: at 1 month, BCVA improved from 20/168 (0.92 logMAR units) to 20/118 (0.78 logMAR units; P = 0.02). the mean BCVA at 24 months was 20/114 (0.76 logMAR units; P<0.0001). in the 1.25-mg group, the mean central macular thickness (CMT) decreased from 466.5 +/- 145.2 mu m at baseline to 332.2 +/- 129.6 mu m at 1 month and 286.6 +/- 81.5 mu m at 24 months (P<0.0001). Similar results were obtained in the 2.5-mg group.Conclusions: Primary IVB at doses of 1.25 to 2.5 mg seem to provide stability or improvement in BCVA, OCT, and FA in DDME at 24 months. the results show no evident difference between IVB at doses of 1.25 or 2.5 mg.Financial Disclosure(s): the author(s) have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2009;116:1488-1497 (C) 2009 by the American Academy of Ophthalmology.
ISSN: 0161-6420
Other Identifiers:
Appears in Collections:Em verificação - Geral

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.